Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO – Get Free Report) shares passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.24 and traded as low as $0.2172. Northwest Biotherapeutics shares last traded at $0.2265, with a volume of 1,945,621 shares changing hands.
Northwest Biotherapeutics Stock Up 4.3%
The company has a market cap of $376.75 million, a PE ratio of -0.01 and a beta of -0.74. The business’s 50 day moving average price is $0.21 and its 200-day moving average price is $0.24.
About Northwest Biotherapeutics
Northwest Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of personalized dendritic cell immunotherapies for the treatment of cancer. The company’s proprietary platform harnesses patient-derived dendritic cells to present tumor-specific antigens and stimulate a targeted immune response. By tailoring each vaccine to the individual patient’s tumor profile, the approach aims to improve outcomes and reduce off-target toxicity associated with conventional therapies.
The company’s lead candidate, DCVax®-L, is designed for patients with newly diagnosed or recurrent glioblastoma multiforme (GBM) and has advanced through a global Phase III clinical trial.
Read More
- Five stocks we like better than Northwest Biotherapeutics
- Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys
- Salesforce Stock Finds Support as AI Momentum Builds
- Dollar Tree Keeps Winning After Family Dollar Divorce
- Apple’s Agentic AI Plans Could Be Its Biggest Growth Story Yet
Receive News & Ratings for Northwest Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Northwest Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
